We are live on ! Find out more
ITRM

Iterum Therapeutics
ITRM

Delisted

ITRM was delisted on the 31st of March, 2026.

Back to rankings

14 hedge funds and large institutions have $19.1M invested in Iterum Therapeutics in 2020 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 2

8% more funds holding

Funds holding: 13 → 14 (+1)

0.01% less ownership

Funds ownership: 3.17% → 3.15% (-0.01%)

40% less capital invested

Capital invested by funds: $31.8M → $19.1M (-$12.7M)

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

Holders
14
Holders Change
+1
Holders Change %
+7.69%
% of All Funds
0.31%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
2
Increased
4
Reduced
2
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
+$52.9K
2
UBS Group
UBS Group
Switzerland
+$29.6K
3
Morgan Stanley
Morgan Stanley
New York
+$8.41K
4
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$5.76K
5
OPS
Orion Portfolio Solutions
Nebraska
+$5.17K

Top Sellers

Rank Fund Capital Flow
1
Ensign Peak Advisors
Ensign Peak Advisors
Utah
-$115K
2
GIM
Granahan Investment Management
Massachusetts
-$9.38K

ITRM Hedge Fund Activity: Q1 2020 in Review

14 of the 4,474 institutional investors tracked by Wall St. Rank reported a position in Iterum Therapeutics (ITRM) for Q1 2020, worth a combined $19.1M — down 40% from $31.8M a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new ITRM positions and 0 closed out — a net gain of 2 holders — while 4 added to existing stakes and 2 trimmed.

The largest buyer was Goldman Sachs, opening a new position worth an estimated $52.9K. The largest seller was Ensign Peak Advisors, cutting an estimated $115K.

  • 14 institutional investors held Iterum Therapeutics (ITRM) as of Q1 2020, up from 13 in Q4 2019.
  • Funds reported $19.1M of Iterum Therapeutics stock for Q1 2020, down 40% quarter-over-quarter.
  • 2 funds opened new Iterum Therapeutics positions in Q1 2020 and 0 closed out, a net change of +2 holders.
  • The largest Iterum Therapeutics buyer in Q1 2020 was Goldman Sachs, an estimated $52.9K added.
  • The largest Iterum Therapeutics seller in Q1 2020 was Ensign Peak Advisors, an estimated $115K sold.

Based on aggregated 13F filings for Q1 2020.